These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 677138)

  • 41. A perspective on drug reaction reporting.
    Schneller GH
    Am J Pharm Sci Support Public Health; 1974; 146(3):70-4. PubMed ID: 4850260
    [No Abstract]   [Full Text] [Related]  

  • 42. Processing and evaluation of adverse drug experience reports at the Food and Drug Administration Center for Veterinary Medicine.
    Keller WC; Bataller N; Oeller DS
    J Am Vet Med Assoc; 1998 Jul; 213(2):208-11. PubMed ID: 9676589
    [No Abstract]   [Full Text] [Related]  

  • 43. Hospital pharmacy program for reporting adverse drug reactions.
    Jacinto MS; Kleinmann K
    Am J Hosp Pharm; 1983 Mar; 40(3):444-5. PubMed ID: 6846353
    [No Abstract]   [Full Text] [Related]  

  • 44. The role of databases in drug postmarketing surveillance.
    Rodriguez EM; Staffa JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expanding and tracking the capabilities of pesticide multiresidue methodology used in the Food and Drug Administration's pesticide monitoring programs.
    McMahon BM; Burke JA
    J Assoc Off Anal Chem; 1987; 70(6):1072-81. PubMed ID: 3436902
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of drugs by the medical letter.
    Abramowicz M
    Am J Hosp Pharm; 1976 Jan; 33(1):71-3. PubMed ID: 1266869
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adverse drug event reporting. Improving the low US reporting rates.
    Edlavitch SA
    Arch Intern Med; 1988 Jul; 148(7):1499-503. PubMed ID: 3382293
    [No Abstract]   [Full Text] [Related]  

  • 48. Adverse behavioral reactions attributed to triazolam in the Food and Drug Administration's Spontaneous Reporting System.
    Wysowski DK; Barash D
    Arch Intern Med; 1991 Oct; 151(10):2003-8. PubMed ID: 1929688
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The medicolegal aspects of adverse drug reactions.
    Bernstein HN; Levine AM
    Int Ophthalmol Clin; 1970; 10(3):455-72. PubMed ID: 5537801
    [No Abstract]   [Full Text] [Related]  

  • 50. Recognizing, reporting, and reducing adverse drug reactions.
    Brown SD; Landry FJ
    South Med J; 2001 Apr; 94(4):370-3. PubMed ID: 11332899
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A survey of adverse drug reaction reporting programs in select hospitals.
    Case RL; Guzzetti PJ
    Hosp Pharm; 1986 May; 21(5):423-6, 431-4, 438. PubMed ID: 10276799
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Target: adverse drug reactions.
    Welsh JS
    Am Pharm; 1979 Aug; 19(9):30-3. PubMed ID: 506916
    [No Abstract]   [Full Text] [Related]  

  • 53. Drug surveillance data in a Canadian hospital.
    Borda IT; Napke E; Stapleton C
    Can Med Assoc J; 1976 Mar; 114(6):517-22. PubMed ID: 1260589
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Food and Drug Administration's Safe Use Initiative collaborating to reduce preventable harm from medications.
    U S Food And Drug Administration
    J Pain Palliat Care Pharmacother; 2010 Mar; 24(1):76-93. PubMed ID: 20345207
    [No Abstract]   [Full Text] [Related]  

  • 55. Discovery of new adverse drug reactions. A review of the Food and Drug Administration's spontaneous reporting system.
    Rossi AC; Knapp DE
    JAMA; 1984 Aug 24-31; 252(8):1030-3. PubMed ID: 6748207
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Food and Drug Administration's Proactive toxic anterior segment syndrome Program.
    Eydelman MB; Tarver ME; Calogero D; Buchen SY; Alexander KY
    Ophthalmology; 2012 Jul; 119(7):1297-302. PubMed ID: 22578447
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug therapy monitoring notes--untapped source of data.
    Riddiough MA
    Am J Hosp Pharm; 1978 Mar; 35(3):241, 243. PubMed ID: 626202
    [No Abstract]   [Full Text] [Related]  

  • 58. The organizational structure and governing principles of the Food and Drug Administration's Mini-Sentinel pilot program.
    Forrow S; Campion DM; Herrinton LJ; Nair VP; Robb MA; Wilson M; Platt R
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():12-7. PubMed ID: 22262588
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fluoroquinolones: A hot topic for pharmacists and the Food and Drug Administration's Division of Drug Information.
    Molnar DM; Kremzner ME
    J Am Pharm Assoc (2003); 2019; 59(1):13-16. PubMed ID: 30348510
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intensified adverse drug reaction reporting scheme.
    N Z Med J; 1977 Jun; 85(589):477. PubMed ID: 271848
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.